CHAMPAIGN, Ill. — A new derivative of a natural compound reduced symptoms associated with multiple sclerosis and promoted the central nervous system’s regenerative pathways in a mouse model, report researchers at the University of Illinois Urbana-Champaign and collaborators at Keio University and Chiba University in Japan.
The compound activates a mitochondrial enzyme that regulates a cellular signaling pathway key for regeneration. The researchers saw improvements in paralysis and changes associated with neural regeneration in the mice, pointing to the compound furapyrrodole, or FP, as a possible drug candidate for further study.
“It may be possible to stimulate the body’s own repair mechanisms to restore damaged nerve cells and myelin in MS,” said Makoto Inoue, an Illinois professor of comparative biosciences who co-led the work with professors Midori Arai of Keio University and Takayoshi Arai of Chiba University. “Our findings identify FP as a promising compound that may help unlock this natural regenerative potential.”
People are also reading…
MS is a neurodegenerative disease in which the immune system attacks and damages the myelin sheaths that cover and protect neurons of the central nervous system. Although treatments are available to suppress relapses and progression, no established therapies can adequately restore neurons or neurological functions that have already been lost.
The research team wanted to find a candidate for treatment that could achieve some functional recovery for MS by promoting the differentiation of neural stem or progenitor cells, which reside in the adult brain and spinal cord, into neurons and myelin-forming cells. They focused on the Notch signaling pathway, which suppresses the differentiation of neural stem or progenitor cells into neurons.
“Inhibition of Notch signaling may help generate neurons and could be an effective therapy for neurodegenerative diseases, including multiple sclerosis,” said Inoue, who also is affiliated with the neuroscience program at the U. of I.
However, conventional Notch inhibitors are associated with adverse gastrointestinal effects. So the researchers set out to screen compounds derived from natural products that could indirectly suppress Notch signaling by binding with an intermediary.
Using specialized cells developed by the Keio group to measure Notch activity, the research team screened the Chiba chemical library and identified Notch-inhibitory activity in a class of compounds called spirooxindoles. After synthesizing and further screening derivatives, they identified FP as the most promising candidate.
The researchers found that FP targets a mitochondrial enzyme, CYB5R3, and enhances its enzymatic activity. This activation resulted in hyperpolarization of the mitochondrial membrane and a reduction in calcium ion levels in the cell. Consequently, this reduced the activity of a calcium-dependent enzyme that plays a key role in Notch signaling.
Inoue’s group at Illinois then tested FP in a mouse model of MS. The mice demonstrated improvements in movement and lessened paralysis. In the spinal cord, suppression of Notch signaling was accompanied by increased numbers of motor neurons derived from neural progenitor cells and oligodendrocytes, cells that contribute to myelin repair. In addition, Inoue’s team found that FP suppressed inflammation in the central nervous system, which is associated with the progression of MS.
Importantly, FP showed no intestinal side effects because its target, CYB5R3, is highly expressed in neural progenitor cells but only expressed at very low levels in the intestine.
Future studies are needed to further investigate the efficacy, safety and pharmaceutical properties of FP to explore its potential therapeutic applications in MS and other neurological disorders, such as Alzheimer’s disease and amyotrophic lateral sclerosis, Inoue said. The researchers plan to continue exploring its action in mice and neural tissue cultures before moving forward to other models.
“Our findings suggest that FP promotes remyelination by stimulating neural progenitor cells to differentiate into oligodendrocytes,” Inoue said. “In addition, its regenerative effects may support the recovery of damaged neuronal populations. Together, these effects were associated with improved motor function in the mouse model, suggesting that targeting the body’s own regenerative mechanisms may offer a promising therapeutic strategy for restoring neurological function in MS.”
The Japan Science and Technology Agency, the Japan Ministry of Education, Culture, Sports, Science and Technology, and the U.S. National Institutes of Health supported this work.

